Abcuro will apply the capital to a study that could support a biologics license application in inclusion body myositis, a rare inflammatory disorder that leads to worsening muscle weakness. A Phase 2/3 study failed earlier this year, but Abcuro saw positive trends in patients with less severe disease.
Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition.
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Bionyra Pharma’s pipeline includes two drugs that target the signaling protein TL1A, alone and as part of a combination approach to treat inflammatory disorders. The startup’s launch makes it a contender in an emerging drug class that includes late-clinical assets from Merck, Roche, and partners Sanofi and Teva Pharmaceuticals.
Ona Therapeutics’ antibody drug conjugates come from a platform technology that discovers novel antigens intended to enable the therapies to overcome drug resistance. The Spain-based startup’s lead ADC is on track to begin clinical testing in breast cancer.
Isomorphic Labs’ Series B financing is the second largest ever raised by a biotech startup. Like the largest one, Isomorphic is also opaque about its drug programs.
This year, we are hosting a new event called Bullseye: Targeting Healthier Outcomes & Returns on July 23 in Chicago. It's invitation-only and exclusively for healthcare investors and corporate business development leads. Join the waitlist for a chance to be in the room with your peers.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Immunology-focused Windward Bio raised a mega-round of financing to support a lead program in development for respiratory disorders and a second program that could find use in respiratory and dermatological indications. Both drugs are long-acting antibodies that offer a dosing edge over currently available biologic medicines.
While AI makes VC faster, it’s not necessarily wiser. In healthcare, where breakthroughs rarely resemble anything the market has seen before, that distinction is everything.
Kurma Partners’ new fund is the venture capital firm’s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma.
The AI Health Fund launched Treehub, a new residency program designed to back and build healthcare AI startups at the earliest stages, often before companies are even formed. It is supported by prominent figures in the Silicon Valley venture capital world, including Tim Draper and Anne Wojcicki.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Sidewinder Therapeutics and Stipple Bio each raised mega-rounds of financing to support their approaches to improving the targeting abilities of antibody drug conjugates for cancer. Both startups are on track to enter the clinic next year.
There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics.
Katie Jacobs Stanton, founder of Moxxie Ventures, shared some details of how she and her team evaluate healthcare AI startups. She stressed the need for founders with deep industry expertise, differentiated products and realistic distribution strategies.
Vima Therapeutics is expanding to Parkinson’s disease following early clinical results showed proof of concept for its drug in isolated dystonia, a rare neurological movement disorder. The startup says its drug could address the biology underpinning many movement disorders.
Nitra announced that it raised $187 million in the past six months. The AI-powered platform — which is now used by more than 700 clinics — manages payments, procurement, inventory, scheduling and insurance verification in a single platform.